The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
PREVENAR 20 (Pfizer Australia Pty Ltd)
Product name
PREVENAR 20
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
Pneumococcal purified capsular polysaccharides
Registration type
NCE/NBE
Indication
Active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older.
Prevenar 20 may not prevent disease caused by S. pneumoniae serotypes that are not contained in the vaccine.
Prevenar 20 should be used in accordance with official recommendations.